Men's Health

The following FAQ highlights key recommendations for urologists from the 2026 AUA Vasectomy Guideline.

A recap of the FDA submissions and regulatory decisions in urology from February 2026.

The sildenafil oral film is expected to be commercially available in the US in March 2026.

The results highlight the early clinical potential of the device for restoring erectile function post-prostatectomy.

The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.

As the year comes to a close, we revisit some of this year’s top content in men's health.

Exogenous testosterone therapy and fertility are fundamentally incompatible.

Regarding compounded testosterone products, Jesse N. Mills, MD, takes a balanced but cautious stance.

Mills warns that poorly justified combination regimens complicate downstream management for urologists.

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

In a panel meeting convened by the FDA, experts urged the agency to revise the current classification and indication for testosterone replacement therapy in men.

Another critical research need involves understanding the effects of exogenous testosterone.

Leila Momtazi-Mar notes that although some studies suggest a decline in retrieval rates after age 40, this association remains preliminary.

Mills describes TRT not merely as a prescription but as an ongoing therapeutic relationship aimed at comprehensive, long-term wellness.

Nicholas Deebel, MD, shared key takeaways from a recent review outlining the current evidence on post-vasectomy pain syndrome.

Muhammed A. Moukhtar Hammad, MBBCh, highlights ongoing work to develop a machine learning model to predict inflatable penile prothesis complications.

Data suggested that most patients do not have a preference on the gender of the urologist who is providing their vasectomy care.

The safety and efficacy of testosterone undecanoate was demonstrated in the phase 3, six-month MRS-TU-2019EXT trial.

Miner emphasized that TRAVERSE has reshaped the safety narrative around testosterone replacement therapy, easing concerns about cardiovascular and prostate risks.

Regarding the timing of sperm retrieval, the findings suggest it is reasonable and safe to delay the procedure until adulthood.

Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes.

Landon Trost, MD, discusses patient-reported outcomes from a study comparing CCH treatment vs surgery for Peyronie's disease.

Ellen Cahill, MD, discusses a recent study on testosterone usage among men interested in fertility.

The study is assessing the safety and tolerability of the CaverSTIM device for ED after surgical removal of the prostate.